Back to Search
Start Over
Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid-β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice.
- Source :
- British Journal of Pharmacology; Jun2020, Vol. 177 Issue 12, p2860-2871, 12p, 5 Graphs
- Publication Year :
- 2020
-
Abstract
- <bold>Background and Purpose: </bold>Immunotherapeutic intervention is one of the most promising strategies for the prevention and treatment of Alzheimer's disease (AD). Although they showed great success in AD mouse models, the clinical trials of many immune approaches failed due to low efficacy and safety. Thus, an animal model which can show the potential side effects of vaccines or antibodies is urgently needed. In this study, we generated EAE/AD mice by crossing APP/PS1 mice with experimental autoimmune encephalomyelitis (EAE) mice. We then investigated the efficacy and safety of two vaccines: the immunogens of which were Aβ1-42 aggregates (Aβ42 vaccine) and an oligomer-specific conformational epitope (AOE1 vaccine), respectively.<bold>Experimental Approach: </bold>EAE/AD mice were immunized with the Aβ42 vaccine or AOE1 vaccine five times at biweekly intervals. After the final immunization, cognitive function was evaluated by the Morris water maze, Y maze, and object recognition tests. Neuropathological changes in the mouse brains were analysed by immunohistochemistry and ELISA.<bold>Key Results: </bold>In contrast to previous findings in conventional AD animal models, Aβ42 immunization promoted neuroinflammation, enhanced Aβ levels and plaque burden, and failed to restore cognitive deficits in EAE/AD mice. By contrast, AOE1 immunization dramatically attenuated neuroinflammation, reduced Aβ levels, and improved cognitive performance in EAE/AD mice.<bold>Conclusion and Implications: </bold>These results suggest that the EAE/AD mouse model can exhibit the potential side effects of AD immune approaches that conventional AD animal models fail to display. Furthermore, strategies specifically targeting Aβ oligomers may be safe and show clinical benefit for AD treatment. [ABSTRACT FROM AUTHOR]
- Subjects :
- AMYLOID plaque
AMINO acid sequence
AMYLOID beta-protein precursor
AMYLOID beta-protein
VACCINATION complications
ALZHEIMER'S disease
MICE
BIOLOGICAL models
RESEARCH
VACCINES
DEMYELINATION
ANIMAL experimentation
RESEARCH methodology
PROTEIN precursors
COGNITION
MEDICAL cooperation
EVALUATION research
COMPARATIVE studies
RESEARCH funding
AMINO acids
ANTIGENS
PEPTIDES
Subjects
Details
- Language :
- English
- ISSN :
- 00071188
- Volume :
- 177
- Issue :
- 12
- Database :
- Complementary Index
- Journal :
- British Journal of Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 143330352
- Full Text :
- https://doi.org/10.1111/bph.15015